Daiichi acquires another ADC drug through Glycotope licensing deal
Daiichi Sankyo is bringing a seventh antibody-drug conjugate, or ADC, into its pipeline through a licensing agreement with German biotech Glycotope.
Specific fin...
Continue Reading →
